Blue Cross & Blue Shield of MississippiAll Plans · Coverage · Medical Policy · Hematology, Oncology, GeneticsMedium impact
Genetic Testing for FLT3, NPM1, CEBPA, IDH1, and IDH2 Variants in Cytogenetically Normal Acute Myeloid Leukemia
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
Genetic testing for FLT3 internal tandem duplication (FLT3-ITD), NPM1, CEBPA, IDH1 and IDH2 variants may be considered medically necessary in cytogenetically normal acute myeloid leukemia (AML). Genetic testing for these variants is considered investigational in all other situations, and testing for FLT3 tyrosine kinase domain (FLT3-TKD) variants is considered investigational. Testing for FLT3, NPM1 and CEBPA variants to detect minimal residual disease is also considered investigational, and the testing is intended to guide management decisions in individuals who would receive treatment other than low-dose chemotherapy or best supportive care.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
01Billing team: Bill genetic testing for FLT3-ITD, NPM1, CEBPA, IDH1 and IDH2 variants as medically necessary only for cytogenetically normal AML, where the policy says it may be considered medically necessary.
02Billing team: Do not bill FLT3-TKD testing, or testing for FLT3, NPM1 and CEBPA variants to detect minimal residual disease, as medically necessary, because the policy considers them investigational.
03Billing team: Treat genetic testing in all other situations as investigational and do not bill it as medically necessary.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.